Genelux Co. (NASDAQ:GNLX) Stock Position Decreased by Woodward Diversified Capital LLC

Woodward Diversified Capital LLC decreased its stake in shares of Genelux Co. (NASDAQ:GNLX) by 5.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,268,305 shares of the company’s stock after selling 75,058 shares during the quarter. Genelux comprises about 2.2% of Woodward Diversified Capital LLC’s investment portfolio, making the stock its 8th biggest holding. Woodward Diversified Capital LLC owned about 3.67% of Genelux worth $2,993,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Geode Capital Management LLC raised its holdings in Genelux by 39.7% in the 3rd quarter. Geode Capital Management LLC now owns 316,160 shares of the company’s stock worth $749,000 after acquiring an additional 89,854 shares during the last quarter. LifeSteps Financial Inc. raised its stake in shares of Genelux by 17.6% in the third quarter. LifeSteps Financial Inc. now owns 78,255 shares of the company’s stock worth $185,000 after purchasing an additional 11,719 shares during the last quarter. Exchange Traded Concepts LLC lifted its holdings in shares of Genelux by 89.0% during the third quarter. Exchange Traded Concepts LLC now owns 65,930 shares of the company’s stock valued at $156,000 after purchasing an additional 31,047 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new stake in shares of Genelux during the second quarter valued at $56,000. Finally, XTX Topco Ltd bought a new stake in Genelux in the 3rd quarter worth about $59,000. 37.33% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on GNLX shares. HC Wainwright lowered their target price on shares of Genelux from $32.00 to $30.00 and set a “buy” rating on the stock in a research note on Friday, November 15th. Guggenheim assumed coverage on shares of Genelux in a research report on Tuesday, October 29th. They set a “buy” rating and a $8.00 price objective on the stock. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $18.25.

Genelux Stock Down 3.4 %

Shares of NASDAQ:GNLX opened at $4.28 on Friday. The stock has a market capitalization of $147.83 million, a PE ratio of -4.51 and a beta of -1.48. The firm’s 50 day moving average price is $2.87 and its 200-day moving average price is $2.59. Genelux Co. has a twelve month low of $1.60 and a twelve month high of $9.82.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.